Atypical Facial and Scalp Lupus Erythematosus Tumidus: Diagnostic Challenges from Long-Term Misdiagnosis and Conflicting Histopathology Authors: Menglin Li, Tao Guo, Junling Zhang Published: 2026 ABSTRACT AbstractBackgroundLupus erythematosus tumidus (LET) is a rare photosensitive skin lupus subtype. Its erythematous swelling easily mimics erysipelas, cellulitis or herpes zoster, leading to frequent misdiagnosis. Atypical cases complicated by interface dermatitis and patient self-medication create prominent differential diagnostic difficulties.Case PresentationA 58-year-old woman had scalp and facial erythema swelling for 1 year, worsened over 4 days. She was repeatedly misdiagnosed with bacterial infectious skin diseases and given ineffective antibiotics. Before admission, she took herbal decoctions and received bloodletting acupuncture by herself, aggravating facial edema. Examination showed infiltrative erythema and scalp alopecia. Full autoantibody, complement and routine lab tests were nearly normal. Cheek biopsy showed typical LET mucin deposition and periadnexal lymphocytic infiltration, while scalp biopsy unexpectedly revealed focal basal liquefaction degeneration. The final diagnosis of atypical LET was made after comprehensive clinicopathological evaluation. Combined hydroxychloroquine and methylprednisolone therapy induced obvious lesion remission within 6 months of follow-up.ConclusionThis atypical LET case illustrates key differential diagnostic traps caused by long-term misdiagnosis and conflicting pathological findings. Unsupervised herbal treatment and blood-letting acupuncture disturbs clinical manifestations and delays formal therapy. For patients presenting with facial edematous erythema accompanied by atypical epidermal pathological changes, comprehensive serological screening and thorough histopathological examination are warranted. Early clinicopathological combined diagnosis, antimalarial drugs and strict sun protection help avoid misdiagnosis and recurrence.Keywords: lupus erythematosus tumidus, diagnosis, histopathology Introduction Lupus erythematosus tumidus (LET) was historically classified as a subtype of chronic cutaneous lupus erythematosus (CCLE). According to the 2004 Düsseldorf classification of cutaneous lupus erythematosus (CLE) and subsequent consensus statements from the European Society for Cutaneous Lupus Erythematosus (EUSCLE), LET has been reclassified as a distinct entity termed intermittent cutaneous lupus erythematosus (ICLE).1,2 The hallmark manifestations of LET are edematous, infiltrative erythema or plaques localized to sun-exposed areas including the scalp, face and trunk. The lesions present with smooth surfaces without scaling, follicular plugging, cutaneous atrophy or scarring, and follow a relapsing-remitting clinical course.3 The main differential diagnoses of LET include Jessner–Kanof Infiltrate (Pseudolymphoma), polymorphous light eruption, reticular erythematous mucinosis and granuloma faciale, among others.4 Furthermore, a small subset of atypical LET cases has been documented; unregulated self-treatment can exacerbate inflammatory edema, obscure the characteristic clinical features of LET, and further complicate differential diagnosis. Herein, we report an atypical LET patient with predominant scalp and facial involvement, focal interface dermatitis on histopathology, and a 1-year history of repeated misdiagnoses. We systematically summarize the patient’s clinical manifestations, laboratory findings and histopathological characteristics. Combined with a literature review, we analyze the inconsistency between the patient’s pathological findings and classic diagnostic criteria, as well as the confounding effects of unmonitored self-treatment on clinical presentations. We also summarize key diagnostic clues and therapeutic regimens for LET. This work aims to improve clinicians’ recognition of atypical phenotypes, reduce the risk of prolonged misdiagnosis and inappropriate intervention, and provide references for the early identification and standardized management of comparable challenging cases. Case Presentation A 58-year-old female patient was admitted with the chief complaint of “erythema and swelling of the scalp and face for 1 year, with exacerbation over the preceding 4 days”. The patient reported patchy tumid erythema emerging on the scalp 1 year prior, accompanied by alopecia, which she ignored initially. The skin lesions gradually expanded in size over time. Half a year before admission, swelling developed on the right eyelid and cheek. She sought medical care at multiple hospitals intermittently, where tentative diagnoses of “erysipelas?”, “cellulitis?”, and “herpes zoster?” were raised. She received treatment with penicillin and cephalosporin antibiotics, which induced partial improvement of lesions; however, the condition relapsed promptly after antibiotic discontinuation. She subsequently attended Beijing Tongren Hospital, where oral methylprednisolone 6 tablets daily combined with topical agents were prescribed. As her cutaneous manifestations ameliorated, she self-tapered methylprednisolone to 1 tablet daily, followed by another disease flare characterized by new edematous erythema on the left cheek. Half a month prior to admission, she received oral traditional Chinese herbal decoctions at a local clinic and underwent self-administered bloodletting acupuncture. Four days before hospitalization, facial swelling deteriorated markedly, and she was admitted under the provisional diagnoses of “connective tissue disease? Lupus erythematosus?”. Cutaneous Physical Examination Patchy edematous erythema with prominent infiltration, bright red discoloration and elevated local skin temperature was observed on the scalp and face, accompanied by mild bilateral eyelid swelling (Figure 1A–C). (A–C) Patchy edematous erythema with marked infiltration, bright red discoloration and elevated skin temperature are seen on the scalp and face; mild swelling of bilateral eyelids is present. Laboratory and Auxiliary Examinations Erythrocyte sedimentation rate (ESR): 10 mm/h; serum IgM: 0.36 g/L (decreased). All other laboratory tests, including routine blood analysis, routine urinalysis, antinuclear antibody (ANA) titer and immunofluorescence pattern, anti-double-stranded DNA (anti-dsDNA) antibody, full spectrum of extractable nuclear antigen (ENA) antibodies, and complement C3/C4 levels, were within normal reference ranges. Cardiac ultrasonography, hepatic and renal ultrasonography, and chest computed tomography (CT) revealed no abnormal findings. Histopathological Findings Biopsy specimen from erythema of the right cheek: Mild epidermal spinous layer atrophy; focal lymphocytic infiltration surrounding superficial dermal blood vessels, hair follicles and sebaceous glands, with identical infiltrates present around deep adipose lobules. Alcian blue staining was positive, confirming intercollagenous mucin deposition. Direct immunofluorescence (DIF): IgG (–), IgM (±), IgA (–), C3 (–) at the basement membrane zone. Biopsy specimen from scalp lesions: Mild epidermal hyperkeratosis, attenuated atrophic spinous layer, and basal cell liquefaction degeneration. Focal lymphocytic infiltration was distributed around dermal blood vessels, hair follicles, sebaceous glands and adipose lobules. Alcian blue staining showed positive staining consistent with intercollagenous mucin deposition. DIF: IgG (–), IgM (–), IgA (–), C3 (–) at the basement membrane zone. Lupus erythematosus was diagnosed based on the above histopathological features from the two biopsy sites (Figure 2A and B). (A and B) Focal lymphocytic infiltration around dermal blood vessels, hair follicles, sebaceous glands and fat lobules; mucin deposition among collagen fibers, Alcian blue stain (+). Final Diagnosis Atypical Lupus Erythematosus Tumidus. Therapeutic Regimen The patient received anti-inflammatory and photoprotective treatment with a combination of methylprednisolone and hydroxychloroquine sulfate. The initial maximum daily dose of methylprednisolone was 40 mg, which was gradually tapered as skin lesions improved during the 6-month follow-up period, and the cutaneous manifestations achieved remarkable remission. Discussion LET has been reclassified as a distinct entity termed ICLE, a relatively rare photosensitive autoimmune dermatosis.1,2 Population-based studies demonstrate that the overall annual incidence of CLE ranges from 3.9 to 4.3 per 100,000 person-years, with a prevalence of 70–109 per 100,000.5 Among all CLE subtypes, discoid lupus erythematosus (DLE) accounts for 68% of cases, followed by subacute cutaneous lupus erythematosus (SCLE,18%) and acute cutaneous lupus erythematosus (ACLE,6%), while ICLE constitutes less than 7% of all CLE patients.6 A large European multicenter EUSCLE cohort enrolling 1002 CLE patients identified only 65 isolated ICLE cases (6.5%) across 13 European countries and Brazil.7 Limited population-specific incidence data for ICLE alone are available due to the absence of an independent ICD coding system for this entity, which leads to underreporting and misclassification in registries.7 The exact pathogenesis of LET remains incompletely elucidated, which is presumed to arise from autoimmune responses triggered by the combined effects of endogenous and exogenous stimuli. Recent studies have identified multiple precipitating factors for LET onset and exacerbation, including certain medications (bortezomib, infliximab, adalimumab, etanercept, ustekinumab, several angiotensin-converting enzyme inhibitors, thiazide diuretics, etc), ultraviolet irradiation, tobacco smoking and genetics.7 Kuhn et al collected clinical data from 40 patients with LET and summarized the characteristic features of the disease as follows: (1) Clinical manifestations: nonscarring, erythematous, succulent, urticarialike single or multiple plaques with no surface changes such as follicular plugging; (2) Histopathological features: perivascular and periadnexal lymphocytic infiltration, interstitial mucin deposition, scattered neutrophils in partial cases, epidermal involvement usually was not found, and smudging of the dermoepidermal junction was only occasionally detected, results of direct immunfluorescence staining of lesional skin specimens have mostly been negative for immunoglobulin or complement components; (3) Phototesting: lesions inducible upon UVA and/or UVB irradiation; (4) Favorable therapeutic response to antimalarial agents.8 Nevertheless, there are some forms with overlapping clinical and/or histological features. Some of them are minimal alterations of the epidermis or the dermoepidermal junction, such as slight vacuolar degeneration, or even the absence of mucin dispositions. Such alterations are acceptable and do not exclude the diagnosis of LET, since other clinical criteria are present.9 The patient presented with patchy raised erythema confined to the scalp and face, without scaling or scarring. Cheek biopsy revealed periadnexal lymphocytic infiltration and inter-collagenous mucin deposition in the dermis, in the absence of epidermal lesions. Scalp biopsy showed predominant characteristic interstitial mucin deposition and perivascular-periadnexal inflammatory infiltrates within the dermis; only focal vacuolar degeneration of basal epidermal cells was observed, with localized and mild interface changes. This mild interface alteration was presumed to be related to skin-barrier damage caused by blood-letting acupuncture, which triggered local irritant inflammation and aggravated dermal oedema and inflammatory infiltration. The patient only had non-scarring alopecia and mild reduction in serum IgM levels. ANA titre and immunofluorescence pattern, anti-dsDNA antibody, full ENA panel (anti-Ro/La, anti-Sm, anti-U1RNP), as well as complement C3 and C4 were all within normal ranges. No other cutaneous, haematological, renal or immunological abnormalities were identified; therefore, the diagnostic criteria for systemic lupus erythematosus (SLE) were not satisfied. The patient’s alopecia was considered secondary to local scalp inflammation. Furthermore, there were no DLE-specific features including scar formation, follicular plugging and adherent keratotic scales, allowing differentiation from DLE. The positivity rate of autoantibodies in patients with LET is generally low. In the cohort study of 40 patients by Kuhn et al, ANA were positive in only 10% of cases, and the positivity rates for anti-Ro/SSA and anti-La/SSB antibodies were merely 5%. Most patients with LET show no significant abnormalities in immunological parameters, which is consistent with the laboratory findings in our case.8 Case reports have documented coexistence of LET with other CLE subtypes and even SLE. Long-term follow-up with serial monitoring of immunological markers is required to identify early signs of systemic involvement, particularly in patients with positive ANA, especially in higher titrations.7 Phototesting could not be performed due to institutional equipment limitations, which constitutes an important limitation of this case. Nevertheless, the skin lesions achieved remission following combined treatment with hydroxychloroquine and glucocorticoids. Taken together, this case was diagnosed as atypical TLE predominantly involving the scalp and face. Prior to admission, the patient had taken oral herbal decoctions and received blood-letting acupuncture. Multiple herbal ingredients contain photosensitizing substances such as psoralen, which may induce drug-related photosensitivity, aggravate erythema and oedema in sun-exposed areas, and mimic the manifestations of erysipelas and cellulitis. This represents a key contributing factor for repeated misdiagnosis of bacterial infection by primary-care clinicians. In addition, blood-letting acupuncture disrupts the skin barrier, triggers local irritant inflammation, amplifies dermal oedema and inflammatory infiltration, and obscures the typical clinical and histopathological features of TLE, further increasing the difficulty of differential diagnosis. Rare cases of TLE co-existing with MDA5-positive amyopathic dermatomyositis have been documented in the literature.10 Clinicians should remain alert to the risk of overlapping autoimmune diseases and refrain from making a diagnosis solely based on cutaneous morphology. Hydroxychloroquine sulfate serves as the first-line foundational agent for LET. It blocks photodamage and delays the progression from isolated cutaneous lesions to systemic involvement, and its routine administration is recommended by both domestic and international guidelines. For patients with markedly infiltrative and oedematous lesions, short-term combination with systemic glucocorticoids is indicated. The dosage should be tapered slowly after erythema subsides to prevent disease rebound induced by rapid drug withdrawal.7 Sustained remission of skin lesions was achieved in the present case following six-month combination therapy with hydroxychloroquine and methylprednisolone, confirming the efficacy of this regimen. Topical corticosteroids represent the first-line topical anti-inflammatory therapy for LET.7 Multicentre double-blind controlled trials have demonstrated that 0.1% tacrolimus ointment produces the most rapid improvement in oedematous erythema of LET. A pooled analysis of 25 clinical studies has shown that topical calcineurin inhibitors are safe and effective for localized CLE lesions. Topical calcineurin inhibitors at concentrations of 0.1%, 0.3% and 1% can be used as steroid-sparing alternatives for chronic manifestations without the adverse effect of steroid-induced skin atrophy.11 In terms of lifestyle management, strict smoking cessation and broad-spectrum photoprotection are fundamental measures that can substantially reduce relapse frequency. The elimination of photosensitizing drugs should be also considered, especially in refractory disease, as well as vitamin D supplementation, since vitamin D deficiency can follow lack of sun exposure, as suggested by the S2 guidelines for the treatment of CLE.7,12 Limitations This study has several limitations. First, this is a single-centre, single-case report with a follow-up duration of only six months. Long-term follow-up data are lacking; therefore, we cannot evaluate long-term risks such as disease relapse and phenotypic transition. Second, phototesting was not performed, which represents a required diagnostic test for classic TLE. Third, the patient received self-administered herbal medicine and blood-letting acupuncture prior to admission. These interventions exerted confounding effects on skin lesions, and their influences on clinical and histopathological manifestations cannot be completely isolated. The above-mentioned limitations should be fully considered when interpreting the findings from this case. Conclusion This atypical TLE case highlights that clinicians should maintain a high index of suspicion for TLE in patients with persistent facial edematous erythema, even in the absence of classical histopathological features. A detailed inquiry into the disease course and prior treatment history is essential, and vigilance against the confounding effects of unregulated treatment on disease diagnosis is warranted. For patients with recurrent lesions and suboptimal treatment responses, comprehensive examinations including skin biopsy and autoantibody testing should be implemented at an early stage to establish a definite diagnosis and subtype classification, so that targeted therapy can be initiated. Individualized long-term follow-up with dynamic monitoring of autoantibodies is required for patients with atypical TLE, to timely identify risks of subtype transition and systemic involvement. Acknowledgments Over the course of my researching and writing this paper, I would like to express my thanks to all those who have helped me. Funding Statement The authors declared that financial support was not received for this work and/or its publication. Ethics Approval and Informed Consent The studies involving humans were approved by the Medical and Health Research Ethics Committee of Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital. Written informed consent was obtained from the patient for publication of this case report, including de-identified clinical data, pathological images and photographs of skin lesions. All identifying information has been removed to protect patient privacy. Disclosure The authors report no conflicts of interest in this work. References